Stryker has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OptaBlate basivertebral nerve ablation system (OptaBlate BVN).

The technology is used in a targeted, minimally invasive surgery that can provide long-lasting vertebrogenic pain relief. Adding OptaBlate BVN expands Stryker’s advanced pain therapy solutions and is an intersection of its radiofrequency ablation tech and vertebral access.

The system achieves at least a 1 cm lesion in seven minutes, according to Stryker. A steerable, dynamic curved introducer for targeted performance and microinfusion tech keeps the zone hydrated to reduce impedance errors and prevent charring. OptaBlate BVN features 10-gauge access tools, as well.

“We often see patients with chronic low back pain who have tried multiple treatments—physical therapy, injections, medications—without lasting relief,” said Dr. Jad Khalil, Spine Surgeon at Michigan Orthopaedic Surgeons. “BVNA is a minimally invasive and innovative procedure that targets a key source of this pain, particularly in patients with specific MRI findings. Before BVNA, options for lasting relief were limited. For many, it offers meaningful improvement and can help avoid more aggressive treatments like surgery.”

“We have a long history in radiofrequency ablation, and we’re relentlessly committed to delivering groundbreaking approaches to protect and promote quality of life,” added Kristen Berg, vice president and general manager of Stryker’s Interventional Spine business. “Our legacy providing solutions to reduce pain now continues with OptaBlate BVN, addressing the underserved population suffering from chronic vertebrogenic lumbar pain.”